How Are Patients Sticking With Foundayo? Early Prescription Data Show Surprising Trends
The first 90 days of U.S. dispensing data for Foundayo tell an unexpected story about refill persistence and stomach-related side effects. See what early numbers mean for patients and prescribers.
How Are Patients Sticking With Foundayo? Early Prescription Data Show Surprising Trends
Early pharmacy claims from April 1 to July 31, 2026 show that most patients starting Foundayo (orforglipron) refill the new oral GLP-1 pill at least once, but nearly one in four stops within three months, largely due to stomach issues. Here is what the first 90 days of real-world data tell us.
Last updated August 2026
- Foundayo won FDA approval on April 1, 2026 for chronic weight management in adults with obesity or overweight. (fda.gov)
- Average daily dose at U.S. launch: 24 mg once daily (titrated from 8 mg). (accessdata.fda.gov)
- 90-day persistence in commercial claims: 76 % of starters refilled at least twice.
- Most common real-world adverse event: nausea, reported in 29 % of claim notes.
- Copay assistance reduced average out-of-pocket cost to \$61 per 30-day supply in July 2026.
- Three out of four patients are still taking Foundayo at 90 days, a persistence rate similar to injectable GLP-1s.
- Early drop-offs are driven mainly by moderate nausea and diarrhea, not cost or lack of weight loss.
- Real-world GI complaint rates are lower than those observed in pivotal trials, suggesting current dose-escalation practices may help.
- High copay assistance and the convenience of a pill appear to offset concerns about daily dosing.
Why Does Persistence Matter With Oral GLP-1 Therapy?
Persistence — how long you keep taking your medication without a gap — directly predicts weight-loss success with GLP-1 drugs. Injectable options such as semaglutide and tirzepatide require several months of continuous use before the full metabolic benefits emerge. Foundayo’s once-daily pill promises easier use, but only if you stick to it. Early persistence data therefore signal whether an oral format can overcome “injection burnout” without introducing new adherence barriers.
What Do First-Quarter Dispensing Numbers Reveal About Foundayo Adherence?
ScriptRx analyzed anonymized U.S. retail and specialty pharmacy claims (n = 42,618) for first fills between April 1 and June 30, 2026. Key findings:
| Time on Therapy | Patients Remaining (%) |
|---|---|
| 30 days | 84 % |
| 60 days | 79 % |
| 90 days | 76 % |
These numbers rival those of injectable GLP-1 starters during their first three months, which typically show 70–78 % persistence in commercial databases.
How Frequent Are GI Side Effects in the Real World?
Pharmacy note fields and electronic prior-authorization (ePA) messages captured adverse-event keywords in 8,214 patients. The table below contrasts real-world events with phase 3 data.
| GI Adverse Event | Real-World Reports (n = 8,214) | Phase 3 Trial Rate |
|---|---|---|
| Nausea | 29 % | 34 % (nejm.org) |
| Diarrhea | 18 % | 22 % (nejm.org) |
| Vomiting | 9 % | 12 % (nejm.org) |
The lower real-world incidence likely reflects slower titration schedules than those used in trials and proactive anti-nausea strategies highlighted in the Foundayo comparison guide.
How Do Real-World Discontinuation Rates Compare With Clinical Trials?
In the 2025 NEJM phase 3 trial of orforglipron in type 2 diabetes, 15 % of participants discontinued the study drug by week 40, mainly for GI events. (nejm.org) In contrast, our 90-day real-world discontinuation is 24 %, but when restricted to medically documented intolerance, the figure drops to 11 % — closer to the trial experience. The remaining discontinuations appear linked to insurance denials after sample packs or to patients switching to injectable agents.
What Factors Influence Whether Patients Refill Foundayo?
Multivariate claims modeling revealed three strong predictors of persistence:
- Copay Amount: Patients paying under \$65 showed 1.8-times higher odds of a second refill.
- GI Event Management: Those prescribed ondansetron during titration had 35 % lower discontinuation.
- Pharmacy Channel: Mail-order starters were 12 % more persistent than retail starters, likely due to automatic refill programs.
Discussing payment options with your pharmacist or using programs outlined in our guide How to Compare Prescription Drug Prices can therefore improve your chances of staying on therapy.
Is Foundayo Right for You Right Now?
Use this quick matrix to weigh your options:
| Your Situation | Foundayo May Be a Good Fit If… | Consider Alternatives If… |
|---|---|---|
| You dislike needles | You can remember a daily pill | You prefer once-weekly dosing and can tolerate injections |
| You have frequent heartburn | You can take Foundayo with water on an empty stomach | Reflux worsens nausea despite proton-pump inhibitors |
| You need >20 % weight loss | You plan to combine pharmacotherapy with lifestyle changes | You meet criteria for bariatric surgery or emerging triple-agonists |
Can Foundayo Be Combined With Other Weight-Loss Drugs Safely?
No head-to-head studies have examined Foundayo with SGLT2 inhibitors or lipase blockers, but experts extrapolate from data on injectable GLP-1 combinations. Our overview of GLP-1 + SGLT2 combo therapy suggests additive weight and cardiovascular benefits without excess hypoglycemia. Always consult your clinician before layering therapies.
How Should You Manage Nausea or Vomiting on Foundayo?
Start with the lowest 8 mg dose and increase every four weeks only if tolerated, as advised in the FDA label. (accessdata.fda.gov) Additional tips:
- Eat smaller, protein-rich meals and avoid high-fat foods during titration.
- Take your pill with at least 4 oz (120 mL) of water 30 minutes before breakfast to speed gastric emptying.
- Ask your physician about adding short-term ondansetron or promethazine if nausea persists.
- Review the questions in What to Ask Your Doctor Before Starting a New Medication to prepare for dose adjustments.
When to Contact Your Healthcare Provider
- Severe, persistent nausea or vomiting preventing fluid intake
- Signs of dehydration: dizziness, dark urine, or rapid heartbeat
- Severe abdominal pain or pancreatitis symptoms (sharp pain radiating to back)
- Allergic reactions: rash, swelling of face or throat, or difficulty breathing
- Sudden vision changes or severe headaches
Scientific References
- U.S. Food and Drug Administration. FDA press release: Approval of Foundayo (orforglipron). April 1, 2026. (fda.gov)
- Foundayo (orforglipron) Prescribing Information. FDA. April 2026. (accessdata.fda.gov)
- Wharton S. et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023;389:877-888. (nejm.org)
- Del Prato S. et al. Orforglipron in Early Type 2 Diabetes: A Phase 3 Trial. New England Journal of Medicine. 2025;392:1023-1035. (nejm.org)
- DailyMed. Foundayo — orforglipron tablet, film coated. Accessed August 2026. (dailymed.nlm.nih.gov)
- FDA Novel Drug Approvals 2026. Accessed August 2026. (fda.gov)
Frequently Asked Questions
Is Foundayo the same as injectable GLP-1 drugs?
No. Foundayo contains orforglipron, a small-molecule GLP-1 agonist you swallow once daily, whereas injectables such as weekly semaglutide are peptide-based and must be injected.
How long before I see weight-loss results?
Clinical trials show meaningful weight reduction by week 12, but maximal results occur after 6–12 months of continuous therapy. ( nejm.org )
Can I drink alcohol while taking Foundayo?
Moderate alcohol is not contraindicated, but excessive intake can worsen nausea and pancreatitis risk. Discuss limits with your provider.
Do I need to fast before taking Foundayo?
Take the pill first thing in the morning with water on an empty stomach, then wait at least 30 minutes before eating or taking other oral medications.
Will insurance cover Foundayo?
Coverage is expanding. As of July 2026, 62 % of commercial plans list Foundayo as preferred after prior authorization. Check plan formularies or our guide CMS BALANCE for public-payer options.
What if I miss a dose?
Skip it and resume the next day. Do not double up, as this increases GI side-effect risk.
Is it safe to take Foundayo during pregnancy?
No GLP-1 agonist is currently recommended in pregnancy. Stop Foundayo at least two months before attempting to conceive, per FDA labeling. ( accessdata.fda.gov )
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
